The global HPV testing and PAP test market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.96% during 2025-2033.
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test. These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices.
HPV Testing and PAP Test Market Trends:
The increasing prevalence of cervical cancer, especially amongst the adult demographics. due to presence of papillomavirus is facilitating the need for novel, technologically advanced, and cost-effective HPV and PAP screening, which is one of the major factors primarily driving the market growth. In line with this, the introduction of machine-assisted, plasma- and cell-free deoxyribonucleic acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at the early phase is acting as another growth-inducing factor. This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.
Key Market Segmentation:
Breakup by Test Type:
HPV Test
Pap Test
Co-testing
Breakup by Product:
Instruments
Consumables
Services
Breakup by Application:
Cervical Cancer Screening
Vaginal Cancer Screening
Breakup by End User:
Hospitals and Clinics
Laboratories
Diagnostic Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMerieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
1.How big is the global HPV testing and PAP test market?
2.What is the expected growth rate of the global HPV testing and PAP test market during 2025-2033?
3.What are the key factors driving the global HPV testing and PAP test market?
4.What has been the impact of COVID-19 on the global HPV testing and PAP test market?
5.What is the breakup of the global HPV testing and PAP test market based on the test type?
6.What is the breakup of the global HPV testing and PAP test market based on the product?
7.What is the breakup of the global HPV testing and PAP test market based on the application?
8.What is the breakup of the global HPV testing and PAP test market based on the end user?
9.What are the key regions in the global HPV testing and PAP test market?
10.Who are the key players/companies in the global HPV testing and PAP test market?